8月14日，Core Scientific盘中下跌5.03%，报19.82美元/股，成交额1.27亿美元。消息面上，公司此前公布的Q2每股亏损3.32美元，远超市场预期的每股亏损0.06至0.10美元，亏损幅度同比大幅扩大；此外，与AMD合作中附带的认股权证安排——AMD可按市价认购公司普通股——持续引发稀释担忧。该股此前于8月11日至12日经历超跌反弹，但多家机构此前已指出反弹持续性存疑。尽管B. Riley将目标价上调至42美元、Keefe Bruyette上调评级至跑赢大盘，短期巨额亏损与股权稀释压力仍主导卖压，股价再度回落。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.